share_log

Cantor Fitzgerald Reiterates Overweight on Fulcrum Therapeutics, Maintains $23 Price Target

Benzinga ·  Jul 10 10:10

Cantor Fitzgerald analyst Kristen Kluska reiterates Fulcrum Therapeutics (NASDAQ:FULC) with a Overweight and maintains $23 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment